Hydrodissection of the Hepatoduodenal Ligament

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Percutaneous treatment of liver lesions adjacent to the duodenum exposes the duodenum to the risk of thermal injury, limiting removal and oncologic outcome. In this study the investigators investigate the feasibility of hepato duodenal ligament dissection in the percutaneous treatment of liver lesions adjacent to the duodenum.

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT00852228` - Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy	Phase 2

NCT number	NCT06190821
Study type	Observational
Source	University Hospital, Strasbourg, France
Contact	Julien GARNON, MD
Phone	33 3.69.55.03.04
Email	julien.garnon@chru-strasbourg.fr
Status	Recruiting
Phase
Start date	July 20, 2022
Completion date	February 20, 2025

Hydrodissection of the Hepatoduodenal Ligament — Duodenal

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms